Bristol-Myers Can't Dodge Celgene Investors' Drug Delay Suit
UMB Bank can pursue its claims that Bristol-Myers Squibb improperly delayed U.S. Food and Drug Administration approval of a cancer treatment to avoid paying $6.4 billion owed from a 2019 acquisition...To view the full article, register now.
Already a subscriber? Click here to view full article